Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse

In the present study, we used osteoprotegerin (OPG), which blocks osteoclastogenesis, to correct and thus explain the hypercalcemia that is seen during dietary Mg deficiency in the mouse. Control and Mg-deficient mice received injections for 12 days of either OPG or vehicle only. Serum Ca was similar in Mg-deficient mice treated with OPG and in control mice receiving OPG (9.2±0.3 mg/dl vs. 9.2±0.5). Both groups had significantly higher serum Ca than controls or Mg-deficient animals receiving vehicle alone. Surprisingly, Mg-depleted mice that received OPG in doses that inhibit osteoclastic bone resorption remained hypercalcemic. Because mature osteoclasts still present in the marrow might be hyperactive, we examined osteoclast morphology at the light microscopic and ultrastructural level. Light microscopic examination of trabecular bone showed few osteoclasts in OPG-treated mice. Ultrastructural examination revealed that osteoclasts in OPG-treated mice have decreased contact with the endosteal bone surface and absence of a ruffled border. Because the morphology of the existing pool of mature osteoclasts did not enhance resorption, another mechanism, such as increased intestinal absorption of Ca in Mg-deficient mice, likely contributes to the hypercalcemia observed during Mg deficiency.     

Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients

Osteoprotegerin (OPG) gene polymorphisms (T245G, T950C and G1181C) have been associated with osteoporosis and early predictors of cardiovascular disease. The aim of this study was to evaluate whether these polymorphisms contribute to cardiovascular disease (CVD) in type 2 diabetic patients. We performed a case-control study with 178 CVD subjects with diabetes and 312 diabetic patients without CVD to assess the impact of variants of the OPG gene on the risk of CVD. The OPG gene polymorphisms were analyzed by using the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). There was no significant association between the T245G and G1181C polymorphisms and CVD in the additive genetic model (OR = 0.96, 95% CI 0.64–1.45, p = 0.79; OR = 1.06, 95% CI 0.81–1.39, p = 0.65, respectively). However, the C allele of the T950C polymorphism was independently associated with a risk of CVD in type 2 diabetic patients in this genetic model (OR = 1.38, 95% CI 1.07–1.80, p = 0.01). This study provides evidence that the C allele of the T950C polymorphism is associated with increased risk of CVD in diabetic patients. However, well-designed prospective studies with a larger sample size are needed to validate these results.     

Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone

Parathyroid hormone (PTH) has biphasic effects on bone: continuous treatment is catabolic whereas intermittent treatment is anabolic. The mechanism(s) responsible for these differing effects are still unclear, partly because of the previous non-availability of a model system in which effects on both formation and resorption indices could be studied concomitantly. In cultured marrow cells from 6-week old C57BL/6 mice, we demonstrated that 4 days of intermittent PTH treatment increased mRNA for osteoblast differentiation markers (Runx2, alkaline phosphatase (AP), and type I procollagen (COL1A1) whereas continuous treatment resulted in production of large numbers of TRAP-positive multinucleated osteoclasts. Although IGF-I mRNA did not increase after intermittent treatment, it was consistently higher than after continuous treatment, and the addition of an anti-IGF-I neutralizing antibody prevented the increase in bone formation indices observed with intermittent treatment. By contrast, after continuous treatment, gene expression of RANK ligand (RANKL) was increased and that of osteoprotegerin (OPG) was decreased, resulting in a 25-fold increase in the RANKL/OPG ratio. In this model system, the data suggest that intermittent PTH treatment enhances osteoblast differentiation through an IGF-I dependent mechanism and continuous PTH treatment enhances osteoclastogenesis through reciprocal increases in RANKL and decreases in OPG.     

人骨保护素N端片段在大肠杆菌中的表达及其活性分析

骨保护素 (OPG)成熟肽N端D1～D4结构域仅由 2个外显子编码 .以人基因组DNA作为模板 ,采用重叠延伸PCR得到N端D1～D4域编码序列 ,并在其上游引入 2×His密码子序列 ,然后克隆入载体pQE 30进行表达 ,SDS PAGE表明 8×His融合蛋白主要以包涵体形式存在 ,可被抗OPG抗体识别 .变性条件下通过Ni NTA金属螯合亲和层析对表达产物进行纯化后再经梯度透析进行复性 ,采用破骨细胞样细胞 (osteoclast likecell ,OLC)诱导分化实验来检测重组蛋白的生物活性 ,证实单核 巨噬细胞集落刺激因子 (M CSF)和破骨细胞分化因子 (ODF)可协同促进多核OLC的生成 ,但加入重组OPG片段后 ,OLC生成显著减少 .     

流体剪应力对成骨细胞OPG和ODF表达的影响

通过平板流动腔装置对大鼠成骨细胞施以流体剪应力,研究剪应力作用对成骨细胞中骨保护因子(osteoprotegerin,OPG),破骨细胞分化因子(osteoclast differentiation factor,ODF)基因表达的影响.分别考察了剪应力大小和作用时间,以及单一水平和梯度变化的剪切力加载方式的影响.运用RT-PCR和蛋白质印迹技术检测OPG、ODFmRNA和蛋白质表达的变化,结果显示,剪切力作用下OPG的表达得到促进,ODF的表达受到抑制,mRNA与蛋白质表达的变化一致,这种影响与剪切力的大小和作用时间有关.1.0和1.5N/m2的剪应力作用效果比0.5N/m2明显,梯度变化的作用方式在作用效果上与最后一个梯度水平相当的恒定剪应力单独作用没有显著差异,在加载的24h内剪应力对OPG、ODF表达的影响始终存在.这种影响使得OPG/ODF的平衡向着OPG占优的方向发展,这种变化意味着骨吸收会受到抑制,提示力学刺激可能通过OPG/ODF调控系统对骨代谢平衡进行调控.